Cargando…
HP1γ Sensitizes Cervical Cancer Cells to Cisplatin through the Suppression of UBE2L3
Cisplatin is the most frequently used agent for chemotherapy against cervical cancer. However, recurrent use of cisplatin induces resistance, representing a major hurdle in the treatment of cervical cancer. Our previous study revealed that HP1γ suppresses UBE2L3, an E2 ubiquitin conjugating enzyme,...
Autores principales: | Yi, Sang Ah, Kim, Go Woon, Yoo, Jung, Han, Jeung-Whan, Kwon, So Hee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503686/ https://www.ncbi.nlm.nih.gov/pubmed/32825184 http://dx.doi.org/10.3390/ijms21175976 |
Ejemplares similares
-
HPV-mediated nuclear export of HP1γ drives cervical tumorigenesis by downregulation of p53
por: Yi, Sang Ah, et al.
Publicado: (2020) -
Suppression and recovery of BRCA1-mediated transcription by HP1γ via modulation of promoter occupancy
por: Choi, Jae Duk, et al.
Publicado: (2012) -
Citrullination of HP1γ chromodomain affects association with chromatin
por: Wiese, Meike, et al.
Publicado: (2019) -
The lncRNA UBE2R2-AS1 suppresses cervical cancer cell growth in vitro
por: Liu, Chunyan, et al.
Publicado: (2020) -
Two Enhances the Cisplatin Sensitivity of Cervical Cancer Cells via Suppression of c-MET Expression
por: Chen, Ziqin, et al.
Publicado: (2023)